Oncological and surgical outcomes after resection of gastrointestinal neuroendocrine tumors – a retrospective analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037925

Enrollment

250

Registered

2026-02-10

Start date

2026-03-01

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal neuroendocrine tumors (GI-NETs) C15-C26

Interventions

Group 1: In this retrospective study, pseudonymized routine data are collected from patient records. Demographic data, clinical parameters, diagnoses, treatments and outcomes are extracted. Data colle

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who underwent surgical treatment for a histologically confirmed neuroendocrine tumor between January 1, 2005, and December 31, 2025.

Exclusion criteria

Exclusion criteria: Absence of histological confirmation of a neuroendocrine tumor Incomplete documentation of essential parameters

Design outcomes

Primary

Measure	Time frame
•overall survival (OS) •disease-free survival (DFS)	—

Secondary

Measure	Time frame
PATIENT-SPECIFIC BASELINE CHARACTERISTICS • Age at initial diagnosis • Sex • Body mass index (BMI) • Comorbidities and pre-existing conditions (by organ system, ASA score, Karnofsky performance status) • Medication history • Exposure to noxious substances (alcohol, tobacco, other drugs) • Family history (genetic syndromes in the family, familial clustering of malignancies) • Initial presentation (clinical symptoms vs. asymptomatic incidental finding) • Date of diagnosis • Date of surgery PREOPERATIVE DIAGNOSTICS AND THERAPY • Preoperative imaging (MRI, CT, somatostatin receptor scintigraphy, PET-CT, EUS, TTE) • Preoperative histology (if biopsy performed) • Preoperative cTNM staging; differentiation between functional NET (fNET) and non-functional NET (nfNET); exact entity (insulinoma, gastrinoma, glucagonoma, VIPoma); surgery performed under an alternative suspected diagnosis • Preoperative laboratory values (complete blood count, creatinine, urea, AST, ALT, GGT, bilirubin, albumin, prothrombin time/INR, aPTT, total protein, CRP) • Tumor-specific laboratory values such as insulin, C-peptide, chromogranin A, NSE, 5-HIES; screening for MEN1 (serum calcium, PTH, prolactin) • Tumor localization and number • Neoadjuvant therapy (somatostatin analogues / targeted therapies / chemotherapy / PRRT / other) INTRAOPERATIVE VARIABLES • Extent of surgery (organ-preserving vs. organ-resecting; for pancreatic surgery: enucleation / papillary resection / pancreatic head resection / spleen-preserving distal pancreatectomy / distal pancreatectomy with splenectomy / total pancreatectomy / other) • Surgical approach (open / laparoscopic / robot-assisted), conversion rate • Duration of surgery (skin incision to closure time) • For pancreatic surgery: portal vein resection and clamping time, pancreatic duct diameter, pancreatic parenchyma texture (soft vs. hard), reconstruction • Concomitant resection of other organs • Perioperative antibiotic therapy • Intraop	—

Measure

Time frame

PATIENT-SPECIFIC BASELINE CHARACTERISTICS • Age at initial diagnosis • Sex • Body mass index (BMI) • Comorbidities and pre-existing conditions (by organ system, ASA score, Karnofsky performance status) • Medication history • Exposure to noxious substances (alcohol, tobacco, other drugs) • Family history (genetic syndromes in the family, familial clustering of malignancies) • Initial presentation (clinical symptoms vs. asymptomatic incidental finding) • Date of diagnosis • Date of surgery PREOPERATIVE DIAGNOSTICS AND THERAPY • Preoperative imaging (MRI, CT, somatostatin receptor scintigraphy, PET-CT, EUS, TTE) • Preoperative histology (if biopsy performed) • Preoperative cTNM staging; differentiation between functional NET (fNET) and non-functional NET (nfNET); exact entity (insulinoma, gastrinoma, glucagonoma, VIPoma); surgery performed under an alternative suspected diagnosis • Preoperative laboratory values (complete blood count, creatinine, urea, AST, ALT, GGT, bilirubin, albumin, prothrombin time/INR, aPTT, total protein, CRP) • Tumor-specific laboratory values such as insulin, C-peptide, chromogranin A, NSE, 5-HIES; screening for MEN1 (serum calcium, PTH, prolactin) • Tumor localization and number • Neoadjuvant therapy (somatostatin analogues / targeted therapies / chemotherapy / PRRT / other) INTRAOPERATIVE VARIABLES • Extent of surgery (organ-preserving vs. organ-resecting; for pancreatic surgery: enucleation / papillary resection / pancreatic head resection / spleen-preserving distal pancreatectomy / distal pancreatectomy with splenectomy / total pancreatectomy / other) • Surgical approach (open / laparoscopic / robot-assisted), conversion rate • Duration of surgery (skin incision to closure time) • For pancreatic surgery: portal vein resection and clamping time, pancreatic duct diameter, pancreatic parenchyma texture (soft vs. hard), reconstruction • Concomitant resection of other organs • Perioperative antibiotic therapy • Intraop

—

Countries

Germany

Contacts

Public ContactSophia Chikhladze

Universitätsklinikum Freiburg

sophia.chikhladze@uniklinik-freiburg.de+4976127024010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026